Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 168,099 |
|
|||||
| News | - | ||||||
| Day High | 13.97 | Low High |
|||||
| Day Low | 13.46 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Liquidia Corporation | LQDA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.35 | -2.53% | 13.46 | 12:18:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.68 | 13.46 | 13.97 | 13.81 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,868 | 168,099 | $ 13.70 | $ 2,302,460 | - | 5.71 - 16.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:18:08 | 3 | $ 13.46 | USD |
Liquidia Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.03B | 76.03M | - | 17.49M | -78.5M | -1.03 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Liquidia News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LQDA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.33 | 15.34 | 13.395 | 13.81 | 731,075 | -1.87 | -12.20% |
| 1 Month | 16.72 | 16.99 | 13.395 | 14.94 | 870,550 | -3.26 | -19.50% |
| 3 Months | 11.95 | 16.99 | 11.83 | 14.57 | 821,511 | 1.51 | 12.64% |
| 6 Months | 5.86 | 16.99 | 5.71 | 11.92 | 962,974 | 7.60 | 129.69% |
| 1 Year | 6.92 | 16.99 | 5.71 | 10.34 | 747,280 | 6.54 | 94.51% |
| 3 Years | 2.79 | 16.99 | 2.25 | 6.96 | 754,955 | 10.67 | 382.44% |
| 5 Years | 8.99 | 16.99 | 2.25 | 6.11 | 641,152 | 4.47 | 49.72% |
Liquidia Description
| Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. |
